Physician

Internal Medicine

Dr. Uchenna H. Iloeje, MD

Uchenna Iloeje is an expert in the field of Internal Medicine. Uchenna Iloeje has written publications. He has 45 publications published with PubMed. The lastest paper is: 'Association between hypoglycemia and fall-related events in type 2 diabetes mellitus: analysis of a u.s. Commercial database.'

Publications

Association between hypoglycemia and fall-related events in type 2 diabetes mellitus: analysis of a u.s. Commercial database.
Determinants of glycaemic control in a practice setting: the role of weight loss and treatment adherence (The DELTA Study).
Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic me...
Synergistic Effects of Family History of Hepatocellular Carcinoma and Hepatitis B Virus Infection on Risk for Incident Hepatocellular Carcinoma.
Associations between claims based adherence, weight loss and, glycemic control in patients with type 2 diabetes.
Improvement in liver histology among Asian patients with chronic hepatitis B after long-term treatment with entecavir.
Absenteeism and productivity among employees being treated for hepatitis C.
Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C.
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
Long-term outcomes in hepatitis B: the REVEAL-HBV study.
Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study.
Cost of chronic hepatitis B infection in the United States.
Hepatitis B management costs in France, Italy, Spain, and the United Kingdom.
Cost of chronic hepatitis B infection in China.
Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection.
Increased use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors.
Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B.
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.
Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men.
Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social S...
The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons.
Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review.
Global epidemiology of hepatitis B virus.
Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection.
Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.
Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort.
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study.
Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS.
Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.
Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study.
Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.
Risk and predictors of mortality associated with chronic hepatitis B infection.
Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study.
Hepatitis B virus DNA levels and outcomes in chronic hepatitis B.
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma.
Incidence of hepatocellular carcinoma among individuals with hepatitis B virus infection identified using an automated data algorithm.
Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.
Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death.
96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients.

Schools

University of Nigeria College of Medicine
University Of Connecticut School Of Med

Doctors Specialties

Internal Medicine

Accepted Insurances

Education

Yale-New Haven Hospital
University of Pittsburgh Medical Center
University of Connecticut
University of Nigeria Faculty of Medicine

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Maria E. Quinones, MD
	Dr. Anna George, MD This Doctor is OpenDoctor Recommended.
	Dr. Myra Rosenstein, MD This Doctor is OpenDoctor Recommended.